<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110682</url>
  </required_header>
  <id_info>
    <org_study_id>DR 2004-05</org_study_id>
    <nct_id>NCT00110682</nct_id>
  </id_info>
  <brief_title>Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses</brief_title>
  <official_title>A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derm Research @ 888 Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Derm Research @ 888 Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Aims:&#xD;
&#xD;
        -  To compare the long-term efficacy and safety of imiquimod versus vehicle used as an&#xD;
           adjunct to cryotherapy.&#xD;
&#xD;
        -  To assess and compare the recurrence rate and time to recurrence of the 2 different&#xD;
           treatment groups.&#xD;
&#xD;
      Hypothesis: The imiquimod arm will produce a more prolonged clearing of Actinic Keratoses&#xD;
      (AK) compared to the vehicle arm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of: (i) topical imiquimod 5% cream or (ii) vehicle cream used two times weekly for&#xD;
      eight weeks starting two weeks post cryotherapy.&#xD;
&#xD;
      Study Aims:&#xD;
&#xD;
        -  To assess and compare the recurrence rate and time to recurrence of the 2 different&#xD;
           treatment groups.&#xD;
&#xD;
        -  To assess and compare the efficacy of the 2 different treatment groups.&#xD;
&#xD;
        -  To assess and compare the safety of the 2 different treatment groups.&#xD;
&#xD;
      Study Design: 6 visits over 62 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence rate and time to recurrence of lesions</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach treatment success</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who clear</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient improvement assessment</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Keratosis</condition>
  <condition>Actinic Keratosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod used as an adjunct to cryotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of actinic keratosis with 4 or more discreet lesions on the face or balding&#xD;
             scalp. Lesions must be within a treatment area not exceeding 50 cm2 (combined total&#xD;
             must not exceed 50 cm2)&#xD;
&#xD;
          -  Women of childbearing potential using appropriate contraceptive methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatments with imiquimod for AK in the prescribed area within the past 5&#xD;
             months or cryosurgery in the same area within the past 4 weeks.&#xD;
&#xD;
          -  Patients unwilling to stay out of the sun or wear protective clothing or to use&#xD;
             sunscreen with a minimum of SPF 15 during the study.&#xD;
&#xD;
          -  Basal or squamous cell carcinomas in the prescribed treatment area in the past 2&#xD;
             years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Poulin, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche Dermatologique du Quebec Metropolitaine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerry KL Tan, MD FDRPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>U. of Western Ontario, Windsor Ontario</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Thomas, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Derm Research @ 888 Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch @ 888 Inc</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V4C 6X4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermatologique, CRDQ</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>May 12, 2005</study_first_submitted>
  <study_first_submitted_qc>May 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2005</study_first_posted>
  <last_update_submitted>April 21, 2008</last_update_submitted>
  <last_update_submitted_qc>April 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>D Richard Thomas</name_title>
    <organization>Department of Dermatology and Skin Science</organization>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>Cryotherapy</keyword>
  <keyword>Imiquimod</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

